Form 4: FibroGen Executive Christine Chung Reports Stock Transactions

Christine Chung, SVP of China Operations at FibroGen, reports the acquisition and disposal of company stock to cover tax obligations and vesting of restricted stock units.

Summary

• On March 6, 2025, Christine Chung, SVP of China Operations at FibroGen, engaged in transactions involving FibroGen's common stock.
• 7,008 shares were disposed of to cover tax obligations at a price of $0.39 per share.
• 781 shares were acquired due to the vesting of a PSU Milestone Grant.
• An additional 422 shares were disposed of to cover tax obligations related to the vesting of the PSU Milestone Grant, also at $0.39 per share.
• Following these transactions, Ms. Chung directly owns 294,903 shares of FibroGen common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The vesting of PSU Milestone Grant indicates that performance milestones were achieved.

Future Outlook

The document does not contain any specific forward-looking statements about the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they primarily relate to tax obligations and vesting of restricted stock units for a company executive.
• However, transparency in insider trading activity is important for maintaining investor confidence.

Key Dates